Oncology Institute Inc (TOI) Quote

toi......................https://stockcharts.com/h-sc/ui?s=toi&p=W&b=5&g=0&id=p86431144783

Florida Blue enhances cancer care for thousands of members

December 18 2024 - 4:05PM


Florida Blue, the state's leading health insurer, has launched a new comprehensive oncology care model designed to provide faster access to high-quality cancer care for its myBlue members. This patient-centric program, jointly developed by Florida Blue, Sanitas Medical Centers, and The Oncology Institute (TOI), is available in select areas across Florida and may grow over time to reach more communities in the state.

The Oncology Institute, one of Florida Blue's trusted in-network providers and the leading value-based oncology group in the U.S., offers high-quality cancer care in 14 locations in Central and South Florida. Sanitas Medical Centers provides value-based, comprehensive primary care for nearly half a million Florida Blue members, through their 60 Florida Blue | Sanitas Medical Center locations across Florida.

Through this new program, myBlue members diagnosed with cancer will be quickly connected with their own TOI oncology team, which will develop personalized, evidence-based treatment plans based on the patients’ needs and preferences and will partner with their Sanitas primary care provider to actively support each patient’s overall health and mental well-being. This collaborative approach ensures seamless communication and coordination between primary care physicians, oncologists and patients and their family members for more comprehensive and integrated care.

"We are committed to making affordable health care easier and more accessible for our members and our patients," said Elana Schrader, senior vice president, Health Care Services at Florida Blue, and president of GuideWell Health. "This program is an example of how we're transforming the system to deliver value-based care solutions that improve health outcomes and help keep care more affordable. Together with The Oncology Institute and Sanitas, we're able to begin offering myBlue members rapid access to high-quality cancer care, while also empowering the Sanitas primary care team to manage their overall health and well-being during a critical and often stressful time for patients and their families."

Dr. Raul Daza, chief medical officer for Sanitas, added, "We are confident that through our collaboration with The Oncology Institute our patients will have a better overall care experience and clearer communications as they deal with a disease state that can be challenging and complicated to understand. By partnering with TOI, we are taking proactive steps toward providing the support cancer patients require, which can also include other physical, mental and social needs that are critical to help them comply with their treatment. We believe this partnership will set a new standard for oncology care."

myBlue is a popular Florida Blue health insurance plan for individuals and families who buy their own coverage (not provided by employer group coverage) designed to provide access to affordable and convenient health care through a network of trusted providers, like Sanitas Medical Centers. As an HMO plan, it is centered around the member and the primary care doctor who coordinates all of the patient’s health care needs.

Individuals who are not currently myBlue members can enroll during the current Marketplace open enrollment period which ends on Jan. 15, or anytime during the year if they qualify for a special enrollment. For more information, please visit FloridaBlue.com/MarketplaceEnrollment or call 1-800-876-2227.

About Florida Blue  
Florida Blue, the leading health insurer in Florida, has been providing health solutions to residents of Florida for more than 80 years. Driven by its mission of helping people and communities achieve better health, the company serves more than six million members and all 67 Florida counties. Headquartered in Jacksonville, Fla., with more than 9,000 employees, it is an independent licensee of the Blue Cross Blue Shield Association.

For additional information visit www.FloridaBlue.com. For the latest news and content, visit the Florida Blue Newsroom, and follow Florida Blue on Facebook, LinkedIn, and Instagram @Florida.Blue; and X (formerly Twitter) @FLBlue.

About Florida Blue | Sanitas Medical Centers
Sanitas Medical Centers is a joint venture between two leading health care organizations – GuideWell Mutual Holding Company and Organización Sanitas Internacional, now under the Keralty brand. GuideWell is a U.S.-based not-for-profit mutual holding company and the parent to a family of forward-thinking companies focused on transforming health care. Keralty is a leading multinational health organization serving more than 10.5 million people with presence in the United States, Colombia, Middle East, Mexico, Brazil, Spain, Peru, Venezuela, Philippines, Dominican Republic and Puerto Rico. The companies are collaborating to expand access to high quality and culturally relevant health care in the United States. Find out more at www.MySanitas.com.

About GuideWell
GuideWell comprises Florida’s Blue Cross Blue Shield plan, Florida Blue, which is the leading health insurer in Florida; Triple-S Management, Puerto Rico’s Blue Cross Blue Shield plan and a leading health care services company on the island; GuideWell Health, a portfolio of integrated care delivery organizations providing primary and urgent care at nearly 100 Florida medical centers and affiliate clinics, which includes Florida Blue | Sanitas Medical Centers; Emcara Health, which partners with primary care providers to extend care into the home; GuideWell Source, which provides administrative services to federal health care programs; and WebTPA, a market leading administrator of self-funded employer health plans. The company holds majority or significant interests in a range of health solutions companies including Lucet, a behavioral health care company that provides technology-enabled support to payers, providers, and health plan members.

GuideWell serves 38.5 million people across 50 states, Puerto Rico and the U.S. Virgin Islands, including more than 6 million individuals in Florida.

For additional information visit www.GuideWell.com. For details regarding the company’s community and sustainability efforts, read the GuideWell Impact Report. For the latest news and content, visit the GuideWell Newsroom, and follow GuideWell on Facebook, LinkedIn, Instagram @LifeAtGuideWell, and X @_GuideWell.

About The Oncology Institute
Founded in 2007, TOI is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of over 1.8 million patients including clinical trials, transfusions, and other services traditionally associated with the most advanced care delivery organizations. With over 120 employed clinicians and more than 700 teammates in over 70 clinic locations, TOI is changing oncology for the better. For more information visit www.theoncologyinstitute.com.

Media

The Oncology Institute, Inc.
Daniel Virnich, MD
danielvirnich@theoncologyinstitute.com
(562) 735-3226 x 81125

Revive
Michael Petrone
mpetrone@reviveagency.com
(615) 760-4542

Investors

Solebury Strategic Communications
investors@theoncologyinstitute.com

Will TOI hit .25 tomorrow?

Now, all TOI insiders are buying big shares since Nov 25. Funny game!

https://www.otcmarkets.com/stock/TOI/disclosure

TOI..............................................https://stockcharts.com/h-sc/ui?s=TOI&p=W&b=5&g=0&id=p86431144783

TOI, all insiders are selling currently.
https://www.otcmarkets.com/stock/TOI/disclosure

TOI..........................https://stockcharts.com/h-sc/ui?s=TOI&p=W&b=5&g=0&id=p86431144783

TOI
New 52 week low

Thanks. I like it.

I may approach them about reselling my company's product.

MREO MY FAV BIO

I did. Where do you recommend next?

Is this going to be a better play soon? I am in heavy, and in the red, with LGHL. would appreciate a quick look and feedback on that board, not here. TOI has so many good things going for it - owned by institutions - it is going to be hard for me not to eventually get in here.

The chart has contradictions like yourself and you're posting history ‼️‼️2😂

Glad you listened

You were correct. Took a major haircut.

Glad I did not jump in. Thanks. What do you like?

The Warrants do not expire

until November, 2026. I may start adding them. I can get 10 Ws for every 1 Common.

What important indicators?

TOI appears to be in a strong bullish trend. Its 200-day moving average is upwards sloping and the MACD histogram is above 0. Comparative Relative Strength analysis shows that this issue is outperforming the S&P 500.
As of 3:00 PM ET Friday, 11/03/2023

important indicators going down as stock is going up...red flag!!!!

Can you explain?

Do you know anything about the warrants? Strike price, expiration date, etc.

CHART HAS SOME CONTRADICTIONS

It sure is acting perky.

Nice move AH and Premarket. I'm going to jump in today if the move north continues.

Common goes down.

Warrants go up on very light volume. Hard to figure.

She was under 40 cents in mid June……

I would say she’s is already flying.

Been my best play this year.

TOI...READY TO FLY

TOI...READY TO FLY

MONSTER IN DA MAKING

It’s tripled since mid-June…..

MONSTER PLAY HERE....

TOI BEAUTY BOTTOM HERE ...AI CANCER PLAY

Company repurchasing more shares. Nice…..

August starting out like July…….

On watch. Thx

Keep eye in $Getr over .55. That’s the breakout spot could explode over .70. I’ve been swinging this also.

I have some left yes just don’t want to get to greedy

I hope you’re still holding some. I’m enjoying the ride.

Looks great. I sold some here .89

I don’t want July to end!!!

Holding in today's nasdaq slide and up on the day. .90 is coming next

Yes definitely

Been a nice move the past 2 weeks……

The low volume dips with 100 share trades……

are fishy.

Maybe this proves to be support.

Long term hold for me.

Let’s get more good new out. It’s been holding strong since the last news about stock repurchase plan.

On June 14, 2023, the Board of Directors of The Oncology Institute, Inc. (the “Company”) approved a share repurchase program with authorization to purchase up to 5 million shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”). The Company may repurchase shares from time to time through one or more securities broker-dealers, in open market purchases and negotiated purchases, in each case at price per share not to exceed $0.75. Shares repurchased by the Company pursuant to the share repurchase program shall be returned to the status of authorized but unissued shares of Common Stock.

In connection with the foregoing, on June 14, 2023, the Company entered into a limited consent (the “Limited Consent”), dated as of June 14, 2023, to that certain Facility Agreement, dated as of August 9, 2022 (the “Facility Agreement”), by and among the Company, as borrower, certain of the Company’s subsidiaries from time to time party thereto as guarantors and Deerfield Partners, L.P., as agent for itself and the lenders (collectively, “Deerfield”). The Limited Consent permits the repurchase by the Company on or prior to June 16, 2023, of up to 5,000,000 shares of the Company’s Common Stock in one or more open market or negotiated purchases, in each case at price per share not to exceed $0.75. The actual timing and amount of repurchases are subject to business and market conditions, corporate and regulatory requirements, stock price, acquisition opportunities and other factors. The Limited Consent does not obligate the Company to repurchase any amount of shares, and there can be no assurance that any shares will be repurchased. The Limited Consent also grants a one-time waiver under the Facility Agreement of certain delivery of any notice requirements.

The foregoing description of the Limited Consent does not purport to be complete and is qualified in its entirety by reference to the full text of the Limited Consent, a copy of which is attached hereto as Exhibit 10.1 and incorporated herein by reference.